DPLD Flashcards
(55 cards)
What are the main imaging patterns seen on HRCT?
- Reticular (Linear)
- Nodular
- Ground-Glass
- Consolidation
- Cystic
- Interlobular Thickening
What are the causes of reticular patterns of disease on HRCT?
ACDCUIS (AC/DC Under the Influence of Something
* Asbestosis (similar to UIP, often with pleural plaques)
* Chronic HP
- Often associated with: ground-glass change, air trapping on expiration, centrilobular micronodules
* Drug-induced fibrosis
* Connective Tissue Disease (similar features to UIP)
* UIP
- Typically patchy, sub-pleural and basal
- Other features: loss of architecture of secondary pulmonary lobules, honeycombing, traction bronchiectasis
* Interstitial Pulmonary Oedema
* Sarcoidosis
What are the causes of nodular patterns of disease on HRCT?
- Interstitial Processes
- Eg: Sarcoidosis
- Airspace Disease
- Due to acini becoming visible as nodules
- HP, miliary TB, malignancy, COP (cryptogenic organising pneumonia)
What are the causes of ground-glass change on HRCT?
- Alveolar proteinosis
- Bronchoalveolar cell carcinoma
- Certain IIPs (NSIP, RB-ILD, DIP, AIP)
- Drugs
- Pulmonary oEdema/ARDS
- Fungal (PCP) Infection
- Great Imitator (Sarcoidosis)
- Hypersensitivity Pneumonitis
Changes may also be artefactual:-
* Increased density (breath holding during expiration)
* Mosaic perfusion (chronic thromboembolic disease, gas trapping)
What are the features and causes of consolidation/airspace shadowing on HRCT?
- Features
- Air bronchograms (air-filled bronchi superimposed against opacified alveoli)
- Loss of visibility of adjacent vessels
- Due to filling of alveolar airspaces by infiltrative processes with water/blood/pus/malignant cells/fibrous tissue
- Causes (HOPCODR)
- Alveolar Haemorrhage
- Pulmonary oedema/ARDS
- Pneumonia
- Cancer (bronchoalveolar cell carcinoma, lymphoma)
- Organising Pneumonia
- Drugs
- Rare diseases (eosinophilic pneumonia, alveolar proteinosis)
What are the causes of cystic change on HRCT?
- Causes: EE, LLL, PU
- Septic Emboli
- Centrilobular Emphysema
- LAM (lymphangioleiomyomatosis) – thin-walled cysts, otherwise normal lungs)
- LIP (lymphoid interstitial pneumonia)
- LCH (Langerhans Cell Histiocytosis) – bizarrely shaped cysts and nodules with apical predominance)
- PCP
- UIP
What is the process for and the causes of interlobular septal thickening on HRCT?
- Process:-
- Due to process affecting interlobular septal lymphatics or venules
- Causes
- Pulmonary oedema (smooth thickening)
- Lymphangitis carcinomatosis (irregular, nodular thickening, no architectural distortion)
- Sarcoidosis
- UIP
What are the typical causes of particular distributions of disease seen on HRCT?
- Upper zone
- Silicosis
- Pneumoconiosis
- Chronic sarcoidosis
- Hypersensitivity pneumonitis
- Ankylosing spondylitis
- TB
- LCH
- Lower Zone
- UIP
- CTD
- Asbestosis
- Mid-Zone
- Sarcoidosis
- Pulmonary oedema
- PCP
- Peripheral
- UIP
- Eosinophilic pneumonia
- Drugs (amiodarone)
- Copt (cryptogenic organising pneumonia)
What are the different HRCT features, histological features, onsets and prognosis of the different IIPs?
IIP Onset HRCT Features Histology Prognosis
IPF (prev CFA) Months-years Fibrosis, honeycombing, subpleural/basal distribution, minimal GGO Interstitial fibrosis (foci of proliferating fibroblasts), interspread with normal lung, minimal inflammation Poor
NSIP Months-years GGOs, fine reticulation, basal distribution, minimal honeycombing Varying degrees of inflammation and fibrosis, more uniform than UIP Variable, can be good
COP (cryptogenic organising pneumonia) Months Consolidation, basal, subpleural, peribronchial predominance Plugged alveolar spaces, granulation tissue +/- extension into bronchioles Poor
AIP (Acute Interstitial Pneumonia) Days Diffuse GGO, patchy consolidation Diffuse alveolar damage, interstitial oedema. Follower by fibroblast proliferation and fibrosis Poor
RB-ILD (Respiratory Bronchiolitis) Years (with mild symptoms) Centrilobular nodules, GGOs, thick-walled airways Pigmented macrophages in bronchioles Good
DIP (Desquamative Interstitial Pneumonia) Weeks-months GGOs Pigmented macrophages in alveolars spaces Good
LIP (Lymphoid Interstitial Pneumonia) Years GGOs, reticulations, cysts Diffuse interstitial lymphoid infiltrates Variable
What are the HRCT features of IPF?
- Reticulations – bilateral, basal and subpleural
- Honeycombing
- Traction bronchiectasis
- Minimal/no GGOs
What are the features of BAL in IPF?
- Not routinely required, rarely helpful
- Features:
- Neutrophilia
- Mild eosinophilia (sometimes)
- Marked eosinophilia (>20%) or lymphocytosis (>50%) suggest alternative diagnosis
What are the histological features of IPF?
- Heterogenicity
- Patches of active fibroblastic foci (acute injury)
- Honeycombing/architectural distortion (chronic scarring)
- Areas of normal lung
- Interstitial inflammation is minimal
What is the prognosis of IPF, and what are poor prognostic factors?
- Variable, mean 3-5 years
- Poor prognostic factors:-
- TLCO <40% at presentation
- 6MWT desat <88%
- Decline in FVC ≥10% or TLCO ≥15% in first 6-12/12
- PHT (particularly poor prognosis)
What are the management options for IPF?
Supportive measures
* Pulmonary Rehab – can be repeated annually
* Hypoxia - Oxygen (if pO2 <7.3 or <8 with features of PHTN)
* GORD - PPI +/- motility agents (eg domperidone)
- GORD is common in IPF and may drive fibrosis
* Cough – opiates (codeine, IR morphine, possibly thalidomide)
Antifibrotics
* Pirfenidone
* Nintedanib
* Acetylcysteine
Lung Transplantation
What are the mechanisms, indications, monitoring requirements, side effects and definitions of treatment failure in the antifibrotics for IPF?
- Pirfenidone
- Mechanism: inhibits collagen synthesis, reduces fibroblast proliferation
- Indication: FVC 50-80%
- Monitoring: monthly FBC/LFT for 6/12, then 3-monthly
- S/E: LFT derangement, GI symptoms
- Treatment failure: FVC decline of ≥10% within 1 year
- Nintedanib
- Mechanism: TK inhibitor – inhibits PDGFR, FGFR and VEGFR ( platelet-derived, fibroblast and vascular endothelial growth factor receptors)
- Indication: FVC 50-80%
- Monitoring: monthly FBC/LFT for 6/12, then 3-monthly
- S/E: bleeding (not recommended for patients on anticoagulation), LFT derangement, GI symptoms
- Treatment failure: FVC decline of ≥10% within 1 year
- Acetylcysteine
- Mechanism: antifibrotic and antioxidant
- Widely used, no harm, no evidence of benefit
What are the guidelines (and also realistic requirements) for patients with IPF to be referred for lung transplantation?
- Guidance – all suitable patients should be referred (irrespective of VC)
- Reality – symptomatic, age <65, TLCO <40%, FVC decline ≥10% in 6/12, TLCO decline ≥15% in 6/12, 6MWT desat <88%, acute/rapid deterioration
What are the radiological classifications of NSIP?
- NSIP with IPF-like profile/overlap (NSIP/IPF)
- NSIP with OP profile (NSIP/OP)
- NSIP with HSP profile (NSIP/HSP)
What are the X features of ?
What are the associations and causes of NSIP?
- Idiopathic
- CTD (NSIP can be the first manifestation)
- Drugs
- Infection
- Immunodeficiency (HIV, post-BM transplant, chemotherapy)
What are the clinical features of NSIP?
- Breathlessness/cough
- Weight loss (common)
- Gradual/subacute onset (0.5-3 years from symptoms to diagnosis)
- Basal crackles, later more extensive
- Clubbing (small proportion)
What are the investigations and typical findings of NSIP?
- HRCT
- GGOs, often basal distribution
- Typically more confluent/homogenous pattern than IPF
- Reticulations and traction bronchiectasis may or may not occur
- Honeycombing usually absent (except fibrotic NSIP)
- Physiological Testing
- Spirometry – restrictive
- DLCO – impaired in only 50%
- SpO2 – desaturation on exertion is common
- BAL – lymphocytosis
- Lung Biopsy – often required, with variable histology:-
- NSIP 1 (primarily cellular/inflammation) – interstitial inflammation, no fibrosis
- NSIP 2 (inflammation and fibrosis)
- NSIP 3 (primarily fibrosis) – fibrosis, more homogenous than UIP, lacks fibroblastic foci or honeycombing
What are the diagnostic requirements for NSIP
- Lung biopsy often required
- If presence of CTD -> biopsy often not required
What are the management of NSIP?
- Monitoring - serial PFTs (FVC + TLCO)
- Decrease of 10-15% considered significant
- Treatment
- Prednisolone – 0.5mg/kg
- Bone protection
- Consideration of PPI
- Consideration of PCP prophylaxis (co-trimoxazole 960m mg x3/week)
- Immunosupression if fails to respond to steroids (eg. Azathioprine, MMF)
Define COP
- Cryptogenic = unknown cause, although OP can occur in association with other disease
- Characteristics – ‘plugging’ of alveolar spaces with granulation tissue, sometimes extending into bronchioles